ABIVAX Société Anonyme (EPA:ABVX)
112.60
+4.20 (3.87%)
Nov 26, 2025, 9:44 AM CET
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 1.05M EUR in the quarter ending June 30, 2025, a decrease of -81.34%. This brings the company's revenue in the last twelve months to 6.02M, down -33.90% year-over-year. In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M with 135.94% growth.
Revenue (ttm)
6.02M
Revenue Growth
-33.90%
P/S Ratio
1,360.15
Revenue / Employee
87.29K
Employees
69
Market Cap
8.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
| Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
| Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
| Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
| Dec 31, 2020 | 14.00K | 21.00K | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 45.93B |
| EssilorLuxottica Société anonyme | 27.24B |
| Eurofins Scientific SE | 7.14B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Ipsen | 3.76B |
ABIVAX Société Anonyme News
- 5 days ago - Abivax (ABVX) Shares Surge 11% on Takeover Speculation - GuruFocus
- 5 days ago - Abivax gains amid takeover speculation - Seeking Alpha
- 7 days ago - 6 Healthcare Stocks With Strong Upward Momentum - Benzinga
- 17 days ago - Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026 - Seeking Alpha
- 22 days ago - Abivax (ABVX) Reports Promising Phase 3 Trial Results for Ulcerative Colitis Treatment - GuruFocus
- 6 weeks ago - Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster - Seeking Alpha
- 6 weeks ago - Guggenheim Raises Abivax (ABVX) Price Target to $150 with Buy Rating | ABVX Stock News - GuruFocus
- 7 weeks ago - ABIVAX Société Anonyme (ABVX) Shareholder/Analyst Call Transcript - Seeking Alpha